Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This observational study concluded that anti-Ku antibodies do not specifically indicate any systemic autoimmune disease or associated clinical phenotype.

This study in childhood-onset systemic lupus erythematosus (cSLE) patients found significant gender differences, with males exhibiting more serositis, higher anti-DNA antibody prevalence, and renal involvement, while females experienced more hair loss.

This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.

This study found that among mixed connective tissue disease patients in a tertiary care hospital in Pakistan, Raynaud phenomenon was the most common clinical feature, present in 80% of patients.

This case report describes a 30-year-old female with overlap syndrome involving systemic lupus erythematosus and scleroderma, where individualized treatment significantly reduced her pericardial effusion.

This case report describes a patient with systemic sclerosis and severe alopecia areata who experienced complete resolution of hair loss within four months after treatment with topical steroids, minoxidil, and mycophenolate mofetil.

This review summarizes the roles of Wnt signaling in wound healing but presents no new clinical findings, suggesting potential for Wnt-based therapies to enhance tissue regeneration.

Bimatoprost can cause longer, thicker, darker eyelashes and eyebrows.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

Clascoterone safely promotes hair growth similar to minoxidil.

This study found that cortexolone 17α-propionate (clascoterone) effectively inhibited androgen receptor-regulated transcription and IL-6 synthesis in scalp cells, potentially making it a promising candidate for topical treatment of androgenetic alopecia.

This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.

This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.

In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.

This case series involving 10 patients treated with clascoterone cream 1% for acne vulgaris found it effective and well-tolerated, regardless of severity, age, gender, or ethnicity, and noted additional benefits for related skin conditions.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

This study established a murine chronic graft-versus-host disease model with scleroderma features, showing typical skin changes and cellular infiltrates associated with the condition.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.

This case report describes a rare occurrence of injection site reactions in a 77-year-old woman with eosinophilic fasciitis using subcutaneous methotrexate, marking the first documented instance in this patient population.

This study found that in female patients with COVID-19-related hair loss, diffuse hair loss and antinuclear antibody positivity might be linked to high antibody levels triggered by the infection.

This case report documents the first confirmed mutation-proved instance of Clouston syndrome in a large Chinese-Malaysian family, linked to the c.263C>T (A88V) mutation in the GJB6 gene, with no available treatment but highlighting the importance of genetic counseling.

This study outlines several common home remedies used in India, such as turmeric, ginger, and coconut, highlighting their traditional efficacy in treating minor ailments and emphasizing the importance of balancing traditional and modern medicine for optimal health outcomes.

This review highlights hypochlorous acid's potential benefits in various medical fields due to its antimicrobial and healing properties but stresses the need for further research on dosing and product development.

Researchers created a new mouse model for studying scleroderma.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This study described a Scottish family with hidrotic ectodermal dysplasia featuring variable symptoms such as hypo/oligodontia, thin hair, and heat tolerance, and concluded they exhibited overlapping traits with Clouston syndrome.